Masimo hosted its 2025 Investor Day at the Company's headquarters, providing an update on the long-term strategy for durable growth.
The company highlighted targets including 7%-10% revenue CAGR through 2028 and a clear focus on patient outcomes, technology innovation, and commercial execution.
Masimo reaffirmed its 2025 financial guidance and outlined its pathway to expand its position as a global leader in patient monitoring.
Long-Term Financial Targets
Revenue CAGR of 7%-10%, Operating Margin of ~30% by 2028, Adjusted EPS of $8.00 by 2028, and Operating Cash Flow of ~$1 billion from 2026-2028.
Market Position
Masimo's market-leading position is driven by its mission to deliver innovations that empower clinicians and transform patient care.
Commitment to Value
Commitment to deliver long-term value to patients, shareholders, employees, and partners.
- Masimo's focus on technology innovation and patient outcomes positions it for continued growth and market leadership.
- The company's strategic roadmap for durable growth and margin expansion reflects a clear execution plan towards long-term success.
With a strong focus on patient care and technological innovation, Masimo's 2025 Investor Day showcased a clear pathway for sustained growth and value creation.